Skip to main content
. 2020 Jan 25;12(2):97. doi: 10.3390/pharmaceutics12020097

Figure 2.

Figure 2

Risk assessment of the MEL-albumin nanoparticle formulation. CMA: Critical material attribute; CPP: Critical process parameter; CQA: Critical quality attribute; EE: Encapsulation efficacy; L,M,H: Low, medium, high.